Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 3091 for:    Area Under Curve AND Healthy

PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02785601
Recruitment Status : Completed
First Posted : May 30, 2016
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Brief Summary:
The main objective is to compare the pharmacokinetics in single dose, and effect of food on the trazodone hydrochloride pharmacokinetics prolonged-release tablets.

Condition or disease Intervention/treatment Phase
Depression Drug: Trazodone Hydrochloride prolonged-release tablets Phase 1

Detailed Description:

Trial I single dose (75mg and 150mg), fasting or postprandial comparative pharmacokinetics of trazodone hydrochloride prolonged-release tablets and ordinary formulation; 16 patients (males and females, half and half).

Trial is a 4-period, 4 cross (4x4) Williams crossover design, screened 16 subjects (half males and half females) were randomly divided into four groups (I-1, I-2, I-3, I-4), each 2 men and 2 women, give the following four different crossover treatments:

(A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) Time for drug administration is around 8:00am. Wash-out period is 7 days. Blood sampling will be performed before (0h) and after administration each dose group 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 72.0h.

Trial I. 4X4 Williams design Group Period 1 Period 2 Period 3 Period 4 I-1 A D B C I-2 B A C D I-3 C B D A I-4 D C A B


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics Study of Trazodone Hydrochloride Prolonged -Released Tablets in Chinese Healthy Volunteers
Actual Study Start Date : May 1, 2017
Actual Primary Completion Date : November 30, 2017
Actual Study Completion Date : January 4, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: I-1
This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
Drug: Trazodone Hydrochloride prolonged-release tablets
strength 75mg, 150 mg. Oral administration with 200ml water

Experimental: I-2
This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
Drug: Trazodone Hydrochloride prolonged-release tablets
strength 75mg, 150 mg. Oral administration with 200ml water

Experimental: I-3
This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
Drug: Trazodone Hydrochloride prolonged-release tablets
strength 75mg, 150 mg. Oral administration with 200ml water

Experimental: I-4
This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
Drug: Trazodone Hydrochloride prolonged-release tablets
strength 75mg, 150 mg. Oral administration with 200ml water




Primary Outcome Measures :
  1. Area Under Curve (AUC) [ Time Frame: pre-dose, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration ]
    To observe area under curve characteristics of trazodone hydrochloride prolonged-release tablets in single or multiple dose groups

  2. Area Under Curve (AUC) [ Time Frame: pre-dose, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 hours, 72 hours after administration ]
    To observe area under curve characteristics of trazodone hydrochloride prolonged-release tablets in fasting or high-fat diet groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Weight: all the subjects should be ≥50 kg, BMI within 19~24 kg/m2;
  • Blood pressure: SBP 90-140mmHg,DBP 50-90 mmHg;
  • All the subjects should understand this trial well and sign the inform consent form before participating this study;
  • Subjects should be able to communicate with investigators well and complete this study in accordance with protocol.

Exclusion Criteria:

  • The baseline value of safety evaluation index is considered to be abnormal with clinical significance by investigators before participating the trial.
  • A positive hepatitis B surface antigen result;
  • A positive hepatitis C surface antigen result;
  • A positive test for HIV antibody and syphilis testing;

Any of the abnormalities of ECGs examination occurs in screening period or the first day of administration:

  • With the history of using any drug which will inhibit or induce liver to metabolize drug within 1 month before the study initiation;
  • With the history of administrating any drugs (prescription medicine, over-the-counter drug and Chinese herbal medicine) within 2 week before the study initiation;
  • Past history of heart disease, cardiac failure, myocardial infarction, angina, unknown cause of arrhythmia, point swinging pattern of ventricular tachycardia, ventricular tachycardia, long QT syndrome or long QT syndrome and family history (with genetic proof or there were any close relatives died because of heart disease);
  • History of thyroid disease or past history of thyroid surgery;
  • History of immune system disease (such as thymus disease);
  • With surgery history within 6 months before this study initiation;
  • History of severe digestive disease (such as gallbladder disease with significant clinical significance, jaundice or susceptive jaundice, hepatocellular adenoma, hepatic cavernous hemangioma and the other liver diseases);
  • With history of gastrointestinal, liver and renal disease (no matter it has been cured or not) which will affect drug absorption and metabolism within 6 months before this study initiating;
  • History of any serve cardiocerebral vascular system, respiratory system, metabolic system and nervous system diseases;
  • History of hematological system diseases, such as coagulation disorders;
  • History of tumor;
  • Subjects with hypokalemia and hypocalcemia (according to the lower limit value of the laboratory reference ranges;

Life style:

  • History of alcohol addicted within 6 months before the study
  • Smoking >1 cigarettes a day in the last 3 months prior to this study;
  • History of drug abuse and taking drugs (such as marihuana, cocaine, opium, benzodizepines, amphetamines, barbiturates, tricyclic antidepressant).
  • History of consumption of excessive tea, coffee and/or caffeinated beverage (more than 8 cups/day) within the period of 2 days before the administration and 8 days after administration.
  • History of consumption of grapefruit juice within the period of 2 days before and 8 days after administration.

Others:

  • Subjects who reject to take effective contraceptive measures within the time period after inclusion to 3 months after administration;
  • Subjects with allergic constitution, including those who are allergic to the excipient (microcrystalline cellulose, lactose, aerosil, sodium carboxymethyl starch, magnesium stearate) of this product;
  • History of participating any clinical trial within 3 months before this study, or participating the other clinical trial within the time period of inclusion to one month after the last time visit(after the last time administration);
  • History of blood donation within 3 months prior to this study, or within the time period of inclusion to one month after the last time visit (after the last time administration);
  • Subjects who have food allergy or have any special diet requirements, or who cannot follow the standard diet;
  • Subjects who, in the opinion of the investigator, should not participate in the study.

The female subjects are not eligible for inclusion in this study if she meet any of the following criteria above and below:

  • With the history of consumption of oral contraceptive within one month prior to this study;
  • History of long-acting estrogen or progesterone injection or implant within 6 months prior to this study;
  • The bearing-age female subjects who have not taken appropriate contraceptives within 2 weeks prior to this study;
  • The bearing-age female subjects and their spouse are not willing to take the following contraceptives measure, condom, copper intrauterine device within 3 months after inclusion;
  • Subjects who are in gestation period and lactation period;
  • Subjects with positive hCG test;
  • Single menstrual more than 80ml.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02785601


Locations
Layout table for location information
Hong Kong
Prince of Wales Hospital
Hong Kong, Hong Kong
Sponsors and Collaborators
Lee's Pharmaceutical Limited
Investigators
Layout table for investigator information
Principal Investigator: Andrea On Yan Luk Prince of Wales Hospital

Layout table for additonal information
Responsible Party: Lee's Pharmaceutical Limited
ClinicalTrials.gov Identifier: NCT02785601     History of Changes
Other Study ID Numbers: Zhaoke-201603-Tra-Trial I
First Posted: May 30, 2016    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Trazodone
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents